• This large, retrospective real-world analysis of NVAF patients with obesity found that treatment with apixaban was associated with a similar risk of stroke/SE and a significantly lower risk of MB versus warfarin
  • No significant interactions were observed between obesity status and treatment in association with outcomes
  • These results support existing clinical trial data and real-world evidence comparing apixaban versus warfarin
    treatment in patients with NVAF
  • These data may inform future research and clinical decision-making in this patient population